Intellia Therapeutics Expected Earnings Report

Intellia Therapeutics (NASDAQ: NTLA) is set to release its quarterly earnings report on Thursday, February 27th, before the market opens. Analysts predict that the company's earnings per share will be around ($1.39) with expected revenue of $8.10 million for the quarter.

Stock Performance Overview

The Intellia Therapeutics stock began trading at $12.28 recently. With a market capitalization of $1.25 billion, the company has a price-to-earnings ratio of -2.26 and a beta of 1.80, indicating its volatility compared to the market. Over the past year, the stock has experienced lows of $8.96 and highs of $34.87. The 50-day moving average is currently at $11.07, while the 200-day moving average stands at $16.12.

Insider Transactions

Recent insider activity includes a significant stock sale by CEO John M. Leonard, who sold 26,807 shares on January 3rd for an average price of $12.18, totaling $326,509.26. Following this transaction, he retains ownership of 941,115 shares, valued at approximately $11.46 million, marking a 2.77% decrease in his holdings. Additionally, during the last 90 days, insiders have sold a total of 29,000 shares worth $352,551. Currently, corporate insiders own about 3.20% of Intellia Therapeutics shares.

Changes in Analyst Ratings

Intellia Therapeutics has been the subject of several recent analyst evaluations. BMO Capital Markets downgraded their price target from $70.00 to $50.00, maintaining an “outperform” rating on January 10th. Similarly, Barclays cut their price target from $76.00 to $55.00 while giving it an “overweight” rating back in November 2023. The Goldman Sachs Group also revised their price expectation downward from $19.00 to $12.00, indicating a “neutral” stance on January 14th. Other firms, including Robert W. Baird and Morgan Stanley, have followed suit with their own adjustments, marking a cautious outlook for the stock. Presently, analysts have issued one sell rating, six hold ratings, eleven buy ratings, and one strong buy rating. MarketBeat shows a consensus rating of “Moderate Buy” for the stock with an average target price of $48.71.

Overview of Intellia Therapeutics

Intellia Therapeutics, Inc. specializes in genome editing and focuses on developing potential curative therapies. Among its various programs, NTLA-2001 is currently in Phase 1 clinical trials targeting transthyretin amyloidosis, while NTLA-2002 aims to address hereditary angioedema. Additionally, NTLA-3001 is under development for alpha-1 antitrypsin deficiency linked to lung disease.

Intellia, Earnings, Stocks